Trikafta Age Expansion in Cystic Fibrosis Agents Clinical Prior Authorization Begins Sept. 1

Published on
July 1, 2021

On June 8, 2021, the U.S. Food and Drug Administration (FDA) approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for patients 6 through 11 years of age with at least one copy of the F508del mutation or specific mutations in the cystic fibrosis transmembrane conductance regulator gene based on lab data.

HHSC will update the formulary and the Cystic Fibrosis Agents prior authorization criteria on September 1, 2021, to reflect the FDA’s recent age expansion.

HHSC does not require MCOs to implement this prior authorization. However, MCOs may revise their prior authorization criteria accordingly to match the updated version by September 1, 2021.